EG-VEGF human
SIGMA/SRP4571 - recombinant, expressed in mouse cell line, ≥98% (SDS-PAGE), ≥98% (HPLC)
Synonym: Endocrine-
Product Type: Chemical
VEGF Pathway Research areas: Angiogenesis, Metastasis, Hypoxia, Osteogenesis, Developmental biology Disease areas: Cancer, Osteoporosis, Ischemic stroke, Inflammation, Rheumatoid Arthritis, Diabetes See also: SRP3182; SRP4363; V5765; SRP4634; SRP4364; SRP4365, SRP3184
| assay | ≥98% (HPLC) |
| ≥98% (SDS-PAGE) | |
| biological source | human |
| form | lyophilized |
| impurities | endotoxin, tested |
| mol wt | ~9.5 kDa |
| NCBI accession no. | P58294   |
| packaging | pkg of 50 μg |
| recombinant | expressed in mouse cell line |
| shipped in | wet ice |
| storage temp. | −20°C |
| UniProt accession no. | P58294 |
| Biochem/physiol Actions: | Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is involved in angiogenesis, inflammatory responses and hematopoiesis. It also participates in female reproduction. EG-VEGF suppresses trophoblast invasion in pregnancy. Changes in the activity of this protein are associated with gestational complication, such as gestational trophoblastic diseases, repeated pregnancy losses, preeclampsia and intrauterine fetal growth restriction. EG-VEGF interacts with G protein-coupled receptors, prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). It is also involved in the pathology of Leydig-cell-tumors, papillary thyroid cancer, neuroblastoma, prostate cancer, gastrointestinal tumors, pancreatic ductal adenocarcinoma, Merkel cell carcinoma and multiple myeloma. |
| General description: | Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) belongs to the prokineticin family. It is mainly expressed in the steroidogenic glands (ovary, testis, adrenal cortex and placenta). EG-VEGF is a small, secreted peptide and works as a tissue-specific pro-angiogenic mitogen and chemotactic agent. The gene is mapped to human chromosome 1p13. |
| Physical form: | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution: | Centrifuge the vial prior to opening. Avoid freeze-thaw cycles. |
| Reconstitution: | Reconstitute in sterile PBS to a concentration of 0.1-1.0 mg/mL containing 0.1% BSA. This solution can then be diluted into other aqueous buffers |
| Purity | ≥98% (HPLC); ≥98% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |